Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Nirav Desai

Interventional Cardiology Bakersfield, CA Medical Doctor

NPI 1790911352 CMS profile 308943

3838 San Dimas St Ste B201, Bakersfield, CA 93301

Open in the dashboard

General payments

$3,615

65 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Nirav Desai of Bakersfield, CA is reported in the CMS Open Payments database as having received $3,615 across 65 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 31st percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $452 5
2023 General $923 15
2022 General $521 9
2021 General $311 7
2020 General $583 13
2019 General $826 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nirav Desai
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Nirav Desai were reported at $0. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Nirav Desai Interventional Cardiology median Middle half National median
2019 $826 $1,097 $329–$3,048 $163
2020 $583 $473 $161–$1,480 $114
2021 $311 $677 $233–$1,827 $132
2022 $521 $978 $333–$2,724 $149
2023 $923 $1,136 $382–$2,986 $160
2024 $452 $1,181 $395–$3,326 $164
2025 $0 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Abiomed $807 12 payments
  2. Boston Scientific Corporation $731 11 payments
  3. Medtronic, Inc. $571 5 payments
  4. Abbott Laboratories $548 9 payments
  5. Medtronic Vascular, Inc. $280 9 payments
  6. Edwards Lifesciences Corporation $184 4 payments
  7. W. L. Gore & Associates, Inc. $175 2 payments
  8. GlaxoSmithKline, LLC. $125 1 payment
  9. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $64 3 payments
  10. Covidien LP $55 4 payments
  11. Other $76 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $3,434 61 payments
  2. Grant $100 1 payment
  3. Travel and Lodging $61 2 payments
  4. Education $21 1 payment
Products named General payments · program years 2019–2024
  1. Impella $807 12 payments
  2. COREVALVE EVOLUT R $384 3 payments
  3. CARDIOFORM Septal Occluder $175 2 payments
  4. 3F $157 4 payments
  5. XIENCE SIERRA $149 2 payments
  6. PORTICO $146 1 payment
  7. EPIC $145 1 payment
  8. TRELEGY ELLIPTA $125 1 payment
  9. WATCHMAN $119 1 payment
  10. GENERAL STENTS $100 1 payment
  11. Other $775 26 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 58 drugs

Part D claims

6,963

Median for Interventional Cardiology: 2,236

Drug cost

$704,944

Median for Interventional Cardiology: $380,412

Branded share of claims

32.8%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 404 $199,442
Eliquis Apixaban Brand 89 $129,206
Pradaxa Dabigatran Etexilate Mesylate Brand 336 $97,242
Repatha Sureclick Evolocumab Brand 45 $45,782
Brilinta Ticagrelor Brand 25 $32,829
Entresto Sacubitril/Valsartan Brand 38 $32,461
Repatha Pushtronex Evolocumab Brand 32 $22,048
Xarelto Rivaroxaban Brand 19 $20,690
Clopidogrel Clopidogrel Bisulfate Brand 630 $11,949
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 292 $9,392

The 10 drugs with the highest cost, of 58 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Records

65 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record